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Pleomorphic lobular carcinoma (PLC) is a histological variant of invasive lobular carcinoma
(ILC) and is associated with worse prognosis than classical ILC. It exhibits a greater degree
of cellular atypia and pleomorphism and is occasionally accompanied with apocrine mor-
phology. We investigated the immunohistochemical characteristics of samples from 31 Jap-
anese patients with PLC to elucidate the clinicopathological characteristics of PLC including
androgen receptor (AR) immunoreactivity. The surrogate molecular subtypes were luminal
A-like, luminal B-like, luminal B-like/HER2, HER2-type, and triple-negative in 5, 4, 3, 5, and
14 cases, respectively. AR was positive in 92.8% (13/14) of the triple-negative PLC cases
and 100% (10/10) of the non-triple-negative PLC cases. Disease-specific survival was
worse in patients with histological grade 3 PLCs than in those with histological grade 2 PLCs
(p = 0.007). However, there was no significant difference in the progression-free survival
between the two groups (p = 0.152). No other clinicopathological characteristics were asso-
ciated with prognosis. These results reveal that PLC exhibits various surrogate molecular
subtypes and that the triple-negative subtype frequently expresses AR. The observed
molecular apocrine differentiation implicates that triple-negative PLC can be categorized
into the luminal AR subtype. Furthermore, AR-targeted therapy might be useful for patients
with triple-negative PLC.
Introduction
Invasive lobular carcinoma (ILC) comprises 10%–15% of all breast cancers [1]. Currently, the
World Health Organization defines ILC as an invasive carcinoma composed of dyscohesive
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cells individually dispersed or arranged in a single-file linear pattern in a fibrous stroma [2].
Typical ILCs infrequently exhibit nuclear atypia and mitoses. ILC is characterized by the
reduced expression of CDH1 that encodes E-cadherin [3]. Loss of E-cadherin is detected via
immunohistochemistry in approximately 90% of ILCs [1–3]. Conversely, most ILCs are fre-
quently positive for estrogen receptor (ER) and progesterone receptor (PgR), whereas they are
frequently negative for human epidermal growth factor receptor 2 (HER2) [1, 2]. Furthermore,
HER2 amplification is rarely detected in ILC via fluorescent in situ hybridization.
Pleomorphic lobular carcinoma (PLC) is a rare histological variant of ILC [4–7]. Although
retaining the characteristic growth pattern of ILC, PLC exhibits more significant cellular atypia
and pleomorphism compared with the classical ILC [5, 6]. In addition, several studies have
reported apocrine differentiation in PLC [6–8]. Most PLC cases exhibit PLC in situ (PLCIS)
surrounding the invasive component [9]. In contrast to the classical ILC, PLC tends to be
HER2-positive as detected by immunohistochemistry [8]. Further, the overall survival of
patients with PLC appears to be inferior to that of patients with classical ILC [4].
Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by the lack
of expression of ER, PgR, and HER2. TNBC can be genetically classified into four subtypes:
basal-like including BL1 and BL2, mesenchymal, and luminal androgen receptor (LAR). The
LAR subtype is characterized by augmented androgen receptor (AR) signaling [10, 11]. Several
studies have developed specific molecular classifications of TNBC, including the LAR subtype
[11–13]. One study reported that the pathologic complete response was worst in patients with
LAR subtype of TNBC among all TNBC molecular subtypes [13]. Interestingly, apocrine carci-
noma, a special type of breast cancer, typically exhibits the immunohistochemical profile of
TNBC with AR positivity [14]. These findings suggest that apocrine carcinoma may be closely
related to the LAR subtype of TNBC. Moreover, some researchers recommend that morpho-
logical and IHC criteria (apocrine morphology in >90% of cells together with ER and PR neg-
ativity and AR positivity in at least 10% of tumor cell nuclei) should be used to define apocrine
carcinoma [15]. AR-positive TNBC, referred to as molecular apocrine breast cancer, typically
arises in older women and has a relatively better prognosis than AR-negative TNBC [14, 16–
19]. Although PLCs apocrine features have been reported, previous studies have not confirmed
AR positivity in triple-negative PLC [6–8, 20, 21].
This study aims to describe the clinicopathological findings of 31 patients with invasive
PLC in Japan with review of the literature including AR immunoreactivity.
Materials and methods
Case selection
In this study, we enrolled 31 Japanese patients with invasive PLC, including 22 patients from
Hiroshima City Hiroshima Citizens Hospital and 9 patients from Okayama University Hospi-
tal, who were diagnosed between 2012 and 2018. Histologic diagnoses were based on the 5th
edition of the World Health Organization classification [2]. All cases were reviewed by two
pathologists (S.T. and K.T. for cases from Hiroshima City Hiroshima Citizens Hospital, and
M.O. and K.T. for cases from Okayama University Hospital) to confirm PLC morphology,
such as the presence of large nuclei, prominent nucleoli, and pleomorphism. Additionally, E-
cadherin negativity was confirmed via immunohistochemistry. The follow-up data were avail-
able for all cases. The use of patient specimens and medical records was approved by the Insti-
tutional Review Board of Okayama University, Japan (IRB approval number:1906–004). The
consent was not obtained because of lost follow up or death from the disease. Instead of
informed consent, we use opt out on the website. The IRB of Okayama University have
approved this method. The study has been performed in accordance with the ethical standards
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laid down in the Declaration of Helsinki. All data were fully anonymized after we accessed
them. From 2015 to 2016, the medical records of 22 patients from Hiroshima City Hiroshima
Citizens Hospital were accessed, and in 2018, those of 9 patients from Okayama University
Hospital were accessed.
Histological analyses
Tissue specimens were fixed with 10% formalin and embedded in paraffin. Sections, 4 μm in
thickness, were stained with hematoxylin-eosin. Histological components, such as ductal carci-
noma in situ, lobular carcinoma in situ, PLCIS, invasive carcinoma of no special type (NST),
and ILC, were recorded. Histological grading was based on the Nottingham histological grad-
ing system, as previously reported [22].
Immunohistochemical analyses
Immunostaining was performed using formalin-fixed, 4-μm, paraffin-embedded tissue sec-
tions with the Ventana BenchMark ULTRA system (Roche Diagnostics, Basel, Switzerland)
according to the manufacturer’s instructions. The slides were treated with a deparaffinization
solution followed by epitope retrieval. The list of primary antibodies used in the study is pre-
sented in Table 1. Localization of the antigen-antibody complex was achieved using the Opti-
View Universal DAB Detection Kit (Roche Diagnostics, Basel, Switzerland) for the 22 cases
from Hiroshima City Hiroshima Citizens Hospital and using the ultraView Universal DAB
Detection Kit (Roche Diagnostics, Basel, Switzerland) for the 9 cases from Okayama Univer-
sity Hospital.
The ER and PgR status was based on the following current definitions: positive,�1%
nuclear staining and negative, <1% nuclear staining [23]. The HER2 status was determined
according to the American Society of Clinical Oncology/College of American Pathologists
Table 1. List of the immunohistochemical antibodies.
Antibody Clone Dilution Distributor Hospital
ER SP1 Prediluted Roche Diagnostics, Basel, Switzerland OUH, HCH
Ready to use
PgR 1E2 Prediluted Roche Diagnostics, Basel, Switzerland OUH, HCH
Ready to use
HER2 4B5 Prediluted Roche Diagnostics, Basel, Switzerland OUH, HCH
Ready to use
Ki-67 MIB-1 1:50 Agilent technologies, Santa Clara, United States. OUH
30–9 Prediluted Roche Diagnostics, Basel, Switzerland HCH
Ready to use
AR SP107 Prediluted Roche Diagnostics, Basel, Switzerland OUH, HCH
Ready to use
GCDFP-15 23A3 1:40 Leica Microsystems, Wetzlar, Germany OUH
1:50 Agilent technologies, Santa Clara, United States. HCH
E-cadherin NCH-38 Prediluted Nichirei Bioscience, Tokyo, Japan OUH
Ready to use
Prediluted Roche Diagnostics, Basel, Switzerland HCH
Ready to use
AR, androgen receptor; ER, estrogen receptor; GCDFP-15, gross cystic disease fluid protein-15; HCH, Hiroshima City Hiroshima Citizens Hospital; HER2, human
epidermal growth factor receptor type 2; OUH, Okayama University Hospital; PgR, progesterone receptor; PLC, pleomorphic lobular carcinoma
https://doi.org/10.1371/journal.pone.0235790.t001
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guidelines [24]. AR immunoreactivity was considered positive in cases with 10% or more
tumor cells that were positive, according to a previous study [25]. The tumor was considered
positive for gross cystic disease fluid protein-15 (GCDFP-15) in the presence of immunoreac-
tivity in any of the tumor cells.
The invasive PLC cases were categorized into five subtypes based on their immunohistochemi-
cal profiles: luminal A-like, luminal B-like, luminal B-like/HER2, HER2-type, and triple-negative,
as defined previously [26]. The cases were categorized as high or low in Ki-67 labeling index (LI)
using the cutoff value of 14% according to the St.Gallen International Expert Consensus [26].
Statistical analysis
To compare disease-specific survival (DSS) and progression-free survival (PFS), survival
curves were generated using the Kaplan–Meier method and analyzed using the log-rank test
with SPSS version 14.0 J (IBM, Armonk, NY). A P value of<0.05 was considered to indicate
statistical significance. DSS was defined as the time from the diagnosis of breast cancer until
the date of death from the disease. PFS was defined as the time from the diagnosis of breast
cancer until the date of first recurrence or progression of the disease or the date of death from
any cause. Patients who were not reported to be dead at the time of the analysis were censored
at the date when they were last known to be alive.
Results
Clinicopathological characteristics
The clinicopathological findings of the patients are summarized in Table 2 (for more details in
the S1 File). The median patient age was 66 (range, 40–86) years. There were 11, 13, 4, and 3
patients with T1, T2, T3, and T4 cancer; the majority of the patients presented with an early T-
stage cancer. Among the patients with T1 PLC, 2, 2, and 7 patients were in the T1a, T1b, and
T1c stages, respectively. Additionally, 14 patients had lymph node metastases, including 1, 4, 5,
and 4 patients in the pNmi, pN1, pN2, and pN3 stages, respectively. Only one patient exhibited
distant metastasis. The proportions of the clinical stages varied in the study cohort; the disease
stages were IA, IIA, IIB, IIIA, IIIB, IIIC, and IV in 10, 6, 4, 3, 2, 4, and 1 patient, respectively.
The representative histological features of invasive PLC are shown in Fig 1. The tumor cells
were dyscohesive with prominent nucleoli and voluminous cytoplasm. Among a total of 31
invasive PLC cases, 23 and 8 cases were histological grades 2 and 3, respectively. Both the glan-
dular formation and nuclear atypia scores were 3 in all 31 cases. The mitotic scores were 1, 2,
and 3 in 23, 4, and 4 cases, respectively. Concurrent tumors were found in nine patients,
including two patients with ductal carcinoma in situ, one patient with apocrine ductal carci-
noma in situ, one patient with invasive carcinoma of NST, two patients with lobular carcinoma
in situ, one patient with PLCIS, and three patients with ILC. One patient had two concurrent
tumors, ILC and DCIS.
Immunohistochemistry
The results of immunohistochemical analyses are summarized in Table 3. The representative
images of immunohistochemical staining in invasive PLC are shown in Fig 1. The rates of posi-
tivity for ER, PgR, and HER2 were 38.7% (12/31), 12.9% (4/31), and 25.8% (8/31), respectively.
The Ki-67 LI was high in 13 cases and low in 15 cases with the following distribution of the KI-
67 LI: 1%–13%, n = 15; 14%–30%, n = 7; 30%–50%, n = 5; 50%–80%, n = 1; not available, n = 3.
The PLC subtypes of the cohort included luminal A-like, luminal B-like, luminal B-like /HER2,
HER2-type, and triple-negative in 5, 4, 3, 5, and 14 cases, respectively (Table 3).
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Immunohistochemical analyses of AR and GCDFP-15 was performed in 24 and 23 PLC
cases, respectively (Table 3). In total, 92.8% of the triple-negative PLC cases (13/14) and 100%
(10/10) of the non-triple-negative PLC cases were positive for AR. Additionally, 100% (11/11)
of the triple-negative PLC cases were positive for GCDFP-15 whereas 66.6% (8/12) of the non-
triple-negative PLC cases were positive for GCDFP-15.
Clinical outcomes
The median follow-up time was 20.7 (range, 3.7–113.9) months. Five patients (16.1%) with
invasive PLC experienced disease-specific mortality (Table 2), including four patients with tri-
ple-negative PLC and one patient with HER2-type PLC.
The DSS and PFS rates of patients with PLC are shown in Fig 2. Briefly, the DSS of the
patients with histological grade 3 PLC was poorer than that of the patients with histological
grade 2 PLC (P = 0.004), although there was no significant difference in the PFS between the
Table 2. Clinicopathological characteristics of patients with invasive PLC.











Histological grade 1 0
2 23
3 8
Glandular formation �2 0
3 31












Follow-up period Range(median) 3.7–113.9 (20.7)
Survival 26
Death 5
DCIS, ductal carcinoma in situ; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; PLC, pleomorphic
lobular carcinoma; PLCIS, pleomorphic lobular carcinoma in situ
https://doi.org/10.1371/journal.pone.0235790.t002
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two groups (P = 0.111). Clinical stage, high Ki-67 LI, and non-triple-negative subtype were not
significant prognostic factors (DSS, P = 0.274, 0.069, and 0.226 and PFS, P = 0.158, 0.249, and
0.227, respectively).
Discussion
PLC is a distinct subtype of ILC that is characterized by significant cellular atypia and pleo-
morphism. In addition, PLCs occasionally exhibit apocrine morphology [2]. Histiocytoid ILCs
also exhibit apocrine morphology [2]. In the WHO 5th edition, histiocytoid ILCs are defined
as tumor cells with pale eosinophilic cytoplasm and low- to intermediate-grade nuclei, resem-
bling histiocytes [2]. In the present study, all PLC cases were of high histological grade (grades
2 or 3) with the highest score of 3 for nuclear atypia. Hence, our study did not include histiocy-
toid ILC. In this small cohort, DSS was better in patients with histological grade 2 PLC than in
those with histological grade 3 via univariate analysis. Patients with histological grade 2 PLC
had a mitotic score of 1 but exhibited conspicuous nuclear atypia. As tumor cells with apocrine
Fig 1. Representative histological and immunohistochemical features of invasive pleomorphic lobular carcinoma. (A) Hematoxylin-eosin staining showing
dyscohesive tumor cells with prominent nucleoli and voluminous cytoplasm. Tumor cells are negative for estrogen receptor (ER) (B) and progesterone receptor (PgR)
(C) and human epidermal growth factor receptor 2 (HER2) (D) and are positive for androgen receptor (AR) (E) and gross cystic disease fluid protein 15 (GCDFP-15)
(F). The Ki-67 labeling index is 30%–50% (G). These findings demonstrate that the tumor is a triple-negative carcinoma with apocrine differentiation. The tumor cells
are negative for E-cadherin (H).
https://doi.org/10.1371/journal.pone.0235790.g001
Table 3. Molecular subtypes of invasive PLCs.
Luminal A-like Luminal B-like Luminal B-like /HER2 HER2 type Triple-negative
PLC 5 4 3 5 14
AR positive 4 3 2 1 13
negative 0 0 0 0 1
GCDFP15 positive 3 2 2 1 11
negative 1 1 1 1 0
AR, androgen receptor; GCDFP-15, gross cystic disease fluid protein 15; HER2, human epidermal growth factor receptor type 2, LAR, luminal androgen receptor; PLC,
pleomorphic lobular carcinoma
https://doi.org/10.1371/journal.pone.0235790.t003
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differentiation often exhibit large nuclei and prominent nucleoli, the nuclear atypia observed
in these cases with histological grade 2 PLC might reflect apocrine differentiation rather than
aggressiveness. Therefore, mitotic score can offer useful information in predicting the progno-
sis of patients with PLC.
It remains controversial whether patients with PLCs have worse prognosis than those with
other invasive breast cancers. Previous reports have demonstrated that the prognosis of inva-
sive PLC is significantly worse than that of invasive carcinoma of NST [6, 7, 27, 28]. In con-
trast, another report has illustrated that PLC is not a prognostic factor compared with invasive
carcinoma of NST via multivariate analysis [29]. In the present study, only five patients with
PLC died of the disease, and it is unlikely that patients with PLC have worse prognosis than
those with other types of breast cancer. However, this result might be due to the relatively early
tumor stage at presentation.
The surrogate molecular subtypes of breast cancer based on immunohistochemistry include
luminal A-like, luminal B-like, luminal B-like/HER2-positive, HER2-type, and triple-negative
[30]. This classification provides critical information necessary for hormone and anti-HER2
therapies [31, 32]. Patients with PLC are more likely to be ER-negative and HER2-positive
than those with classical ILC [4, 33, 34]. Accordingly, the PLC cases in the present study
included luminal A-like (n = 5), luminal B-like (n = 4), triple-negative (n = 14) and 8 HER2--
positive cases comprising luminal B-like /HER2 (n = 3) and HER2-type (n = 5). At present,
Fig 2. Survival analysis of invasive PLC patients with invasive pleomorphic lobular carcinoma. Disease-specific survival (DSS, A–D) and progression-free survival
(PFS, E–H) analyses. The DSS was worse in patients with histological grade 3 cancer than in those with histological grade 2 cancer, although there was no significant
difference in the PFS rates between the two groups. Other factors, including clinical stage, high Ki-67 labeling index, and non-triple-negative subtype were not related to
DSS or PFS.
https://doi.org/10.1371/journal.pone.0235790.g002
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there are no established standard therapies for PLC, and treatment is based on the surrogate
molecular subtypes.
AR positivity is considered essential for demonstrating apocrine differentiation in TNBC
[14, 18, 19]. Several studies have reported AR positivity rates in patients with triple-negative
invasive carcinoma of NST (Table 4) [35–38]. These studies have utilized different anti-AR
antibody clones and different cutoffs for AR positivity. The AR positivity rate in triple-negative
PLC cases in the present study (92.8%) was clearly higher than that previously reported in tri-
ple-negative invasive carcinoma of NST, which ranged from 17.7% to 41% [35–39]. This char-
acteristic, which highlights the apocrine features, indicates that triple-negative PLC can be
classified as the LAR subtype. In a previous report, gene expression analyses described 4 cases
of pleomorphic lobular carcinomas as pertaining to the molecular apocrine subgroup or
HER2-positive group [20]. Among the 31 PLC cases in the present study, however, there were
various surrogate molecular subtypes other than the LAR subtype and HER2-type. Since sur-
rogate classification via IHC is not perfectly correlated with gene expression analyses, further
investigations with a larger sample size should be warranted to clarify the gene expression pro-
file of PLC.
Several studies have reported that AR positivity is associated with a lower risk of recurrence;
on the other hand, a study reported worse outcomes in AR-positive TNBC [36–38, 40]. How-
ever, other studies have not found differences in the recurrence risk between AR-positive and
AR-negative TNBC [39, 41, 42]. Although the prognostic value of AR immunoreactivity in
TNBC remains controversial, preclinical and clinical data have revealed that patients with ER-
negative/AR-positive breast cancer might be candidates for treatment with AR antagonist [43].
We found that most of the triple-negative PLCs were AR-positive, which implicates a crucial
role for AR signaling in triple-negative PLCs. Therefore, patients with triple-negative PLC
might benefit from treatment with AR antagonist. However, the prognosis could not be com-
pared between the AR-positive and AR-negative PLC cases as the cohort included only one
AR-negative PLC case; this comparison should be investigated in further studies.
Several studies have previously illustrated the presence of apocrine differentiation in PLC
using GCDFP-15 [6, 44]. Accordingly, all triple-negative PLC cases (100%) were positive for
GCDFP-15. In addition to the triple-negative PLC cases, all 10 non-triple-negative PLC cases
exhibited AR positivity. Relatedly, nine of these ten non-triple-negative PLC cases were ER-
positive. In agreement with this finding, ER-positive breast cancers have been demonstrated to
frequently express AR and ER [45]. The co-expression of ER and AR have been extensively
studied in the literature. In particular studies by Castellano et al. have shown that AR is
expressed in 70.9% of ER positive breast cancers [46] and that the AR/ER ratio�2 identifies a
subgroup of patients with aggressive biological features and may represent an additional inde-
pendent marker of worse prognosis [47].
Table 4. Published studies on androgen receptor immunoreactivity in triple-negative breast cancer.
Reference Number of cases AR-positive cases (%) Clone Cutoff (%)
Present study 13 92.8% SP107 10%
Doberstein et al, 2014 [35] 52 40.4% SP107 10%
Astvatsaturyan et al, 2018 [36] 135 41% F39.4.1 1%
Choi et al, 2015 [37] 492 17.7% ER179(2) 1%
Gasparini et al. 2014 [38] 396 24.8% F.39.4.1 5%
AR, androgen receptor
https://doi.org/10.1371/journal.pone.0235790.t004
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Despite the rarity of PLC, there are several case series on invasive PLC (Table 5). One case
series included 401 cases of PLCs [4]. However, this case series did not use AR and GCDFP-15 to
confirm apocrine features [4]. Although other researchers have investigated AR positivity in inva-
sive PLCs, they have not mentioned whether these invasive PLCs were triple-negative [20, 21].
Moreover, surrogate molecular subtypes were not considered in all the previous reports [4, 6–8,
20, 28, 33, 48]. To the best of our knowledge, this is the first study of a rare case series of invasive
PLC, which includes various immunohistochemical data and surrogate molecular subtypes.
In conclusion, we reported rare case series of invasive PLC in Japan. We demonstrated that
PLCs exhibit various surrogate molecular subtypes and triple-negative PLCs frequently express
AR, indicating that molecular apocrine differentiation is observed in the LAR subtype. These
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Table 5. Published studies on invasive PLC case series.
Reference Number of
cases





Present study 31 23/24 (95.8%) 22/26 (84.6%) present
Haque et al, 2018 [4] 401 ND ND absent
Buchanan et al, 2008
[28]
52 ND ND absent
Middleton et al, 2000
[8]
38 ND 15/21 (71%) absent
Lien et al, 2015 [33] 21 ND ND absent
Weidner et al, 1992
[7]
16 ND ND absent
Bentz et al, 1998 [48] 12 ND 9/11 (81.8%) absent
Eusebi et al, 1992 [6] 10 ND 10/10 (100%) absent
Weigelt et al, 2008
[20]
4 NA NA absent
AR, androgen receptor, GCDFP-15, Gross Cystic Disease Fluid Protein 15, ND, not done, NA, not available, PLC,
pleomorphic lobular carcinoma
https://doi.org/10.1371/journal.pone.0235790.t005
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